Zilbrysq® (zilucoplan) – New orphan drug approval
October 17, 2023 - UCB announced the FDA approval of Zilbrysq (zilucoplan), for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
Download PDF
